Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026. Performance-based and time-based restricted stock units were exercised under code “M,” delivering additional Guardant Health common shares.
The company retained 4,622 shares at $85.49 per share under code “F” to satisfy Mr. Saia’s tax withholding obligations, as described in the footnotes. After these transactions, he directly owns 56,903 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised equity awards that vested on March 15, 2026. A performance-based restricted stock unit award converted into 12,856 shares of common stock, and a separate restricted stock unit award converted into 637 shares of common stock, both at a price of $0.00 per share.
The company withheld 6,839 shares of common stock at $85.49 per share to satisfy tax obligations related to the vesting, which is treated as a tax-withholding disposition rather than an open-market sale. After these transactions, Kalia directly held 44,297 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into an equal number of common shares at a conversion price of $0.00 per share. To cover tax withholding obligations on this vesting, 7,127 common shares were retained by the company at $85.49 per share, as a tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly holds 53,571 shares of Guardant Health common stock. The performance-based award was granted on June 7, 2023 with a three-year performance metric, and the RSU award was granted on June 9, 2023 with vesting over three years.
Guardant Health Chief Medical Officer Craig Eagle exercised and vested stock awards, with part withheld for taxes. On March 15, 2026, performance-based and time-based restricted stock units covering 13,712 and 1,402 shares of common stock, respectively, were converted into common shares at no exercise price. The company retained 7,661 shares of common stock at $85.49 per share to satisfy Dr. Eagle’s tax withholding obligations related to this vesting, rather than selling shares on the open market. Following these transactions, Dr. Eagle directly holds 66,380 shares of Guardant Health common stock. No remaining derivative awards related to these units are shown after this filing.
Guardant Health Chief Technology Officer Darya Chudova exercised performance-based equity and had shares withheld for taxes. On March 15, 2026, a performance-based restricted stock unit award covering 10,714 units converted into 10,714 shares of common stock after the second performance tranche was achieved.
The company then withheld 5,759 of those common shares, valued at $85.49 per share, to cover tax obligations associated with the vesting, as disclosed in the footnotes. After these transactions, Chudova directly held 64,352 shares of Guardant Health common stock, reflecting a routine compensation-related equity increase rather than an open-market trade.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.
Guardant Health, Inc. reported that Chief Legal Officer John G. Saia received a grant of 20,448 restricted stock units tied to Guardant Health common stock. These RSUs were awarded on March 11, 2026 as part of his equity compensation and do not involve any cash share purchases or sales.
According to the vesting schedule, 33% of the RSUs will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Saia directly holds 20,448 RSUs, which will convert into common shares only as they vest.
Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units on March 11, 2026. These RSUs represent the right to receive an equal number of Guardant common shares as they vest over time.
According to the award terms, 33% of the RSUs will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the following two years. After this grant, Monroe holds 17,040 RSUs directly, reflecting a routine equity compensation award rather than an open‑market purchase or sale.
Kalia Kumud reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Information Officer Kalia Kumud received a grant of 13,632 restricted stock units (RSUs) on March 11, 2026. The award vests over three years: 33% on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Kumud holds 13,632 RSUs directly.